NextCell Pharma (Sweden) Buy Hold or Sell Recommendation
| NXTCL Stock | SEK 1.69 0.01 0.60% |
Assuming the 90 days trading horizon and your above-average risk tolerance, our recommendation regarding NextCell Pharma AB is 'Cautious Hold'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell NextCell Pharma AB given historical horizon and risk tolerance towards NextCell Pharma. When Macroaxis issues a 'buy' or 'sell' recommendation for NextCell Pharma AB, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out NextCell Pharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as NextCell and provide practical buy, sell, or hold advice based on investors' constraints. NextCell Pharma AB. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
NextCell |
Execute NextCell Pharma Buy or Sell Advice
The NextCell recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on NextCell Pharma AB. Macroaxis does not own or have any residual interests in NextCell Pharma AB or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute NextCell Pharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | OK | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
NextCell Pharma Trading Alerts and Improvement Suggestions
| NextCell Pharma AB may become a speculative penny stock | |
| NextCell Pharma AB appears to be risky and price may revert if volatility continues | |
| NextCell Pharma AB has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 5.59 M. Net Loss for the year was (35.02 M) with loss before overhead, payroll, taxes, and interest of (2.49 M). | |
| NextCell Pharma AB has accumulated about 150.75 M in cash with (33.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.39, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 43.0% of the company outstanding shares are owned by corporate insiders |
NextCell Pharma Returns Distribution Density
The distribution of NextCell Pharma's historical returns is an attempt to chart the uncertainty of NextCell Pharma's future price movements. The chart of the probability distribution of NextCell Pharma daily returns describes the distribution of returns around its average expected value. We use NextCell Pharma AB price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of NextCell Pharma returns is essential to provide solid investment advice for NextCell Pharma.
| Mean Return | 0.51 | Value At Risk | -4.89 | Potential Upside | 6.67 | Standard Deviation | 4.00 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of NextCell Pharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
NextCell Pharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to NextCell Pharma or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that NextCell Pharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a NextCell stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.47 | |
β | Beta against Dow Jones | 0.29 | |
σ | Overall volatility | 3.99 | |
Ir | Information ratio | 0.09 |
NextCell Pharma Volatility Alert
NextCell Pharma AB shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure NextCell Pharma's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact NextCell Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.NextCell Pharma Fundamentals Vs Peers
Comparing NextCell Pharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze NextCell Pharma's direct or indirect competition across all of the common fundamentals between NextCell Pharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as NextCell Pharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of NextCell Pharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing NextCell Pharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare NextCell Pharma to competition |
| Fundamentals | NextCell Pharma | Peer Average |
| Return On Equity | -0.3 | -0.31 |
| Return On Asset | -0.17 | -0.14 |
| Operating Margin | (4.75) % | (5.51) % |
| Current Valuation | 134.94 M | 16.62 B |
| Shares Outstanding | 34.38 M | 571.82 M |
| Shares Owned By Insiders | 42.82 % | 10.09 % |
| Shares Owned By Institutions | 5.27 % | 39.21 % |
| Price To Book | 2.01 X | 9.51 X |
| Price To Sales | 37.14 X | 11.42 X |
| Revenue | 5.59 M | 9.43 B |
| Gross Profit | (2.49 M) | 27.38 B |
| EBITDA | (34.08 M) | 3.9 B |
| Net Income | (35.02 M) | 570.98 M |
| Cash And Equivalents | 150.75 M | 2.7 B |
| Cash Per Share | 4.39 X | 5.01 X |
| Current Ratio | 42.29 X | 2.16 X |
| Book Value Per Share | 3.10 X | 1.93 K |
| Cash Flow From Operations | (33.31 M) | 971.22 M |
| Earnings Per Share | (0.81) X | 3.12 X |
| Number Of Employees | 15 | 18.84 K |
| Beta | 0.43 | -0.15 |
| Market Capitalization | 255.91 M | 19.03 B |
| Total Asset | 124.66 M | 29.47 B |
| Net Asset | 124.66 M |
NextCell Pharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as NextCell . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About NextCell Pharma Buy or Sell Advice
When is the right time to buy or sell NextCell Pharma AB? Buying financial instruments such as NextCell Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having NextCell Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Alcohol Thematic Idea Now
Alcohol
Companies involved in production and distribution of wines and alcoholic beverages. The Alcohol theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Alcohol Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for NextCell Stock Analysis
When running NextCell Pharma's price analysis, check to measure NextCell Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NextCell Pharma is operating at the current time. Most of NextCell Pharma's value examination focuses on studying past and present price action to predict the probability of NextCell Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NextCell Pharma's price. Additionally, you may evaluate how the addition of NextCell Pharma to your portfolios can decrease your overall portfolio volatility.